Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition

BACKGROUND: Poly (ADP-ribose) polymerase inhibitors (PARPi) prevent single-stranded DNA repair. Olaparib is a PARPi approved for the treatment of BRCA mutant ovarian and breast carcinoma. Emerging clinical data suggest a benefit of combining olaparib with immunotherapy in prostate cancer patients bo...

Descripción completa

Detalles Bibliográficos
Autores principales: Fenerty, Kathleen E., Padget, Michelle, Wolfson, Benjamin, Gameiro, Sofia R., Su, Zhen, Lee, John H., Rabizadeh, Shahrooz, Soon-Shiong, Patrick, Hodge, James W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6264611/
https://www.ncbi.nlm.nih.gov/pubmed/30486888
http://dx.doi.org/10.1186/s40425-018-0445-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6264611/
https://www.ncbi.nlm.nih.gov/pubmed/30486888
http://dx.doi.org/10.1186/s40425-018-0445-4

Ejemplares similares